CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.
Advertisement
Follow the links below to read about each product:
Articles in this issue
about 2 years ago
Pharmaceutical Executive: July/August 2024 Issue (PDF)about 2 years ago
An AI Pulse Checkabout 2 years ago
A Promising Option: Exxuaabout 2 years ago
Opening the Door: Omvohabout 2 years ago
'Marked’ for Stardom?: Truqapabout 2 years ago
Branching Off: Wegovyabout 2 years ago
A Formidable First: Winrevairabout 2 years ago
The Future of Launch Excellence is Generative AIabout 2 years ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'about 2 years ago
Big Bets, Bold StepsAdvertisement
Related to this article
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5